Key facts: SELLAS Surges 233%, Drops 12%; SLS009 Data Expected Q4 2026
SELLAS (SLS) stock surged 233% on trial news, hitting a 52-week high with 57.6M shares traded. It later fell 12% after a $150M share sale. The company expects Phase 2 data for SLS009 in Q4 2026, according to Coinpedia.
How this was made

The 30-second read
Why it matters
The combination of trial optimism and a sizable equity raise creates a volatile trading environment.
Market read
The news drives short‑term price action in SLS and may influence sentiment toward similar biotech stocks.
What to watch
Potential regulatory scrutiny of the REGAL trial and dilution impact on existing shareholders.
Background
SELLAS Life Sciences Group announced preliminary topline data from its Phase 2 CDK9 inhibitor SLS009 are expected in Q4 2026, prompting a massive price swing.
Ticker impact
SELLAS (SLS) surged 233% on REGAL trial news and fell 12% after a $150 million share sale.
upside pressure from trial news tempered by downside from share dilution
A 233% intraday move indicates strong buying interest, yet a $150 M equity raise typically depresses price.
Market effects
Positive signal for biotech trials may lift peer biotech stocks.
Limited to US biotech market.
Modest; primarily affects niche biotech investors.
Counterpoint
The share sale could trigger a sell‑off that outweighs the trial hype.
Key entities
- companySELLAS Life Sciences Group, Inc.
Biotech firm developing CDK9 inhibitor SLS009.
